Related Experiment Videos
Effects of drug therapy on hypertensive left ventricular hypertrophy
Insights
Effective antihypertensive therapy can reverse left ventricular (LV) hypertrophy. However, severe hypertrophy may only be partially reversible, even with good blood pressure control.
Area of Science:
- Cardiology
- Hypertension Research
- Medical Imaging
Background:
- Essential hypertension frequently leads to left ventricular (LV) hypertrophy.
- LV hypertrophy is a significant risk factor for cardiovascular events.
- Reversibility of LV hypertrophy is crucial for improving patient outcomes.
Purpose of the Study:
- To assess the rate and extent of left ventricular hypertrophy reversal in hypertensive patients.
- To evaluate the impact of antihypertensive therapy on LV mass.
- To determine if severe LV hypertrophy is fully reversible.
Main Methods:
- Serial echocardiography was performed on eight patients with moderate to severe essential hypertension over 12 months.
- Left ventricular (LV) mass was estimated using a validated formula.
- Antihypertensive therapy with multiple drugs was closely supervised.
Main Results:
- LV mass significantly decreased from 206 g/m2 to 168 g/m2 after 6 months of therapy (P < 0.001).
- No further significant reduction in LV mass was observed by 12 months.
- Patients with less severe hypertrophy achieved normal LV mass, while those with severe hypertrophy had persistent elevations.
Conclusions:
- Antihypertensive therapy effectively reduces LV mass in hypertensive patients.
- Severe left ventricular hypertrophy may exhibit only partial reversibility despite adequate blood pressure control.
- Long-term monitoring is essential to assess the full impact of therapy on LV remodeling.
Abstract:
To determine the rate and extent of reversal of left ventricular (LV) hypertrophy, eight patients with moderate to severe essential hypertension (diastolic blood pressure 116 mmHg, s.d. = 8) underwent serial echocardiography during 12 months of closely supervised antihypertensive therapy with multiple drugs. LV cavity size and average wall thickness were measured by sector-directed M-mode echocardiography. LV mass was estimated from a formula which had previously been validated. All subjects had increased LV mass (greater than 125 g/m2). From 6-12 months, 84% of standing diastolic blood pressures, measured monthly, were 90 mmHg or less. During therapy LV mass decreased from 206 g/m2 (s.d. = 98) initially to 168 g/m2 (s.d. = 82) after 6 months (P less than 0.001) with no further significant change by 12 months. In four patients with less severe hypertrophy, LV mass was within the normal range after 6 months of therapy. In four patients with more severe hypertrophy, LV mass remained significantly elevated at 6 and 12 months. Severe hypertensive LV hypertrophy may be only partially reversible, despite good blood pressure control.